Montelukast Svus

Montelukast, the active ingredient in Montelukast Svus, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma, allergic rhinitis and exercise‑induced bronchoconstriction in patients who require control of leukotriene‑mediated airway inflammation.

GNH USA supplies Montelukast Svus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to reduce airway inflammation and bronchoconstriction. - Asthma: improves control of chronic asthma and reduces the frequency of exacerbations. - Allergic rhinitis: relieves nasal congestion, sneezing and itching caused by seasonal or perennial allergies. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Upper respiratory tract infection: symptoms of cold or flu. - Abdominal pain: discomfort in the stomach area. - Cough: occasional dry cough. - Diarrhea: loose stools. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Mood changes: depression, anxiety, or suicidal thoughts. - Allergic reactions: hives, swelling, or difficulty breathing. - Hepatotoxicity: abnormal liver enzyme levels. - Stevens‑Johnson syndrome: severe skin blistering. - Angioedema: rapid swelling of face or throat. - Anaphylaxis: life‑threatening systemic reaction.

Before prescribing Montelukast, consider the following safety measures. - Pregnancy: consult a healthcare professional; safety data are limited. - Breastfeeding: assess risk versus benefit; drug may be excreted in milk. - Liver impairment: monitor hepatic function, especially in severe disease. - Neuropsychiatric effects: observe for mood changes, depression, or suicidal ideation. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines; categorize interactions by clinical relevance.

Major Interactions (Avoid): - Phenobarbital: may reduce montelukast plasma concentrations. - Rifampin: induces metabolism, potentially decreasing efficacy.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may increase risk of neuropsychiatric events. - Warfarin: occasional reports of altered INR; monitor coagulation parameters. - CYP2C9 inhibitors (e.g., fluconazole): could modestly raise montelukast levels. - Herbal supplements (St. John’s wort): may induce metabolism, lowering drug exposure. - Other leukotriene modifiers: additive effects on leukotriene pathways; assess clinical need.